JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keller, S. M.
Right arrow Articles by Johnson, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keller, S. M.
Right arrow Articles by Johnson, D. H.
Related Collections
Right arrow Lung - cancer

J Thorac Cardiovasc Surg 2004;128:130-137
© 2004 The American Association for Thoracic Surgery

General thoracic surgery

Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease

Steven M. Keller, MDa,*, Mark G. Vangel, PhDb, Henry Wagner, MDc, Joan H. Schiller, MDd, Arnold Herskovic, MDe, Ritsuko Komaki, MDf, Randolph S. Marks, MDg, Michael C. Perry, MDh, Robert B. Livingston, MDi, David H. Johnson, MDj for the Eastern Cooperative Oncology Group

a Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, USA
b Department of Biostatistics, Dana Farber Cancer Institute, Boston, Mass, USA
c Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Fla, USA
d Department of Medical Oncology, University of Wisconsin, Madison, Wis, USA
e Department of Radiation Oncology, Oakwood Hospital, Detroit, Mich, USA
f Department of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Tex, USA
g Department of Medical Oncology, Mayo Clinic, Rochester, Minn, USA
h Department of Medical Oncology, University of Missouri, Columbia, Mo, USA
i Department of Medical Oncology, University of Washington, Seattle, Wash, USA
j Department of Medical Oncology, Vanderbilt University, Nashville, Tenn, USA

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication May 20, 2003; revisions received November 5, 2003; accepted for publication November 10, 2003.

* Address for reprints: Steven M. Keller, MD, Department of Cardiothoracic Surgery, The Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
skeller{at}montefiore.org

OBJECTIVES: To test the hypothesis that patients with non–small cell lung cancer and single-level N2 metastases constitute a favorable subgroup of patients with mediastinal metastases, we analyzed the results of the Eastern Cooperative Oncology Group 3590 (a randomized prospective trial of adjuvant therapy in patients with resected stages II and IIIa non–small cell lung cancer) by site of primary tumor and pattern of lymph node metastases.

METHODS: Accurate staging was ensured by mandating either systematic sampling or complete dissection of the ipsilateral mediastinal lymph nodes. The overall survival of patients with left lung non–small cell lung cancer and metastases in only 1 of lymph node levels 5, 6, or 7 and right lung non–small cell lung cancer with metastases in only 1 of levels 4 or 7 was compared with that of patients with N1 disease originating in the same lobe.

RESULTS: The median survival of the 172 patients with single-level N2 disease was 35 months (95% confidence interval: 27-40 months) versus 65 months (95% confidence interval: 45-84 months) for the 150 patients with N1 disease (median follow-up 84 months, P = .01). However, among patients with left upper lobe tumors, survival was not significantly different between patients with N1 disease and patients with single-level N2 disease (49 vs 51 months, P = .63). The median survival of the 71 patients with single-level N2 metastases without concomitant N1 disease (skip metastases) was 59 months (95% confidence interval: 36-107 months) versus 26 months (95% confidence interval: 16-36 months) for the 145 patients with both N1 and N2 metastases (P = .001).

CONCLUSIONS: Survival of patients with left upper lobe non–small cell lung cancer and metastases to single-level N2 lymph nodes is not significantly different from that of patients with N1 disease. The presence of isolate N2 skip metastases is associated with improved survival when compared with patients with both N1 and N2 disease. Survival should be reported by the lobe of primary tumor and metastatic pattern to guide future clinical trial development, treatment strategies, and revisions of the TNM staging system.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
E. Ruffini, P. L. Filosso, M. C. Bruna, F. Coni, R. C. Cristofori, C. Mossetti, P. Solidoro, and A. Oliaro
Recommended changes for T and N descriptors proposed by the International Association for the Study of Lung Cancer -- Lung Cancer Staging Project: a validation study from a single-centre experience
Eur. J. Cardiothorac. Surg., December 1, 2009; 36(6): 1037 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Mohamed, K. Yasufuku, T. Nakajima, K. Hiroshima, M. Chiyo, S. Yoshida, M. Suzuki, Y. Sekine, K. Shibuya, G. Agamy, et al.
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Eur. Respir. J., January 1, 2009; 33(1): 127 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio, A. S. Bryant, and M. A. Eloubeidi
Accessing the Aortopulmonary Window (#5) and the Paraaortic (#6) Lymph Nodes in Patients With Non-Small Cell Lung Cancer
Ann. Thorac. Surg., September 1, 2007; 84(3): 940 - 945.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. A. Whitson, S. S. Groth, and M. A. Maddaus
Surgical Assessment and Intraoperative Management of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer
Ann. Thorac. Surg., September 1, 2007; 84(3): 1059 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. L. Uy, G. Darling, W. Xu, Q.-L. Yi, M. De Perrot, A. F. Pierre, T. K. Waddell, M. R. Johnston, A. Bezjak, F. A. Shepherd, et al.
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 188 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
D. Lardinois, P. De Leyn, P. Van Schil, R. R. Porta, D. Waller, B. Passlick, M. Zielinski, K. Junker, E. A. Rendina, H.-B. Ris, et al.
ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer
Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 787 - 792.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Battafarano
Optimal management of patients with non-small cell lung cancer with ipsilateral mediastinal lymph node metastases
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1227 - 1228.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Ohta, Y. Shimizu, H. Minato, I. Matsumoto, M. Oda, and G. Watanabe
Results of Initial Operations in Non-Small Cell Lung Cancer Patients With Single-Level N2 Disease
Ann. Thorac. Surg., February 1, 2006; 81(2): 427 - 433.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. W. Martin, A. M. Correa, W. Hofstetter, W. K. Hong, R. Komaki, J. B. Putnam Jr, D. C. Rice, W. R. Smythe, S. G. Swisher, A. A. Vaporciyan, et al.
The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1601 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Van Schil, J. Van Meerbeeck, G. Kramer, T. Splinter, C. Legrand, G. Giaccone, C. Manegold, and N. van Zandwijk
Morbidity and mortality in the surgery arm of EORTC 08941 trial
Eur. Respir. J., August 1, 2005; 26(2): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Casali, A. Stefani, P. Natali, G. Rossi, and U. Morandi
Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases
Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 33 - 38.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Patel and J. B. Shrager
Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection?
Oncologist, May 1, 2005; 10(5): 335 - 344.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
A. Iwasaki, T. Shirakusa, S. Enatsu, S. Maekawa, Y. Yoshinaga, S. Yoneda, and S. Hoshino
Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage?
Interactive CardioVascular and Thoracic Surgery, April 1, 2005; 4(2): 126 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
M. Sondhi, J. R. Goffin, B. J. Cohen, J. B. Wong, and S. G. Pauker
DEALE-ing with Lung Cancer and Heart Failure
Med Decis Making, January 1, 2005; 25(1): 82 - 94.
[PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
F. Puma
Isolated mediastinal skip metastasis in lung cancer: Is it real N2 disease?
J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 235 - 235.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The American Association for Thoracic Surgery.